You are here

Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

Last updated on February 20, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-59 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All adult patients with relapsed or refractory AML, as well as younger de novo AML
patients are eligible for the study

- Relapsed, refractory, and de novo AML patients are allowed in Phase I of this study

- Phase II will only allow enrollment of younger de novo AML

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- AML following an antecedent hematologic disorder (myelodysplasia or
myeloproliferation) of greater than 2 months duration

- De novo patients with M3 AML

- AML secondary to exposure to chemotherapy or radiation

NCT00037583
Pfizer
Completed
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Myeloid Leukemia
NCT02038777
All Genders
20+
Years
Multiple Sites
Myelodysplastic Syndrome, Acute Myeloid Leukemia
NCT02367456
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now